UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Kidney international, ISSN 0085-2538, 12/2005, Volume 68, Issue 6, pp. 2823 - 2828
chronic kidney disease | paricalcitol | proteinuria | vitamin D | Chronic kidney disease | Vitamin D | Paricalcitol | Proteinuria | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Urinary tract. Prostate gland | Nephrology. Urinary tract diseases | Biological and medical sciences | Kidneys | Medical sciences | Urinary system involvement in other diseases. Miscellaneous | Hyperparathyroidism, Secondary - metabolism | Hyperparathyroidism, Secondary - drug therapy | Administration, Oral | Humans | Middle Aged | Male | Treatment Outcome | Renal Insufficiency, Chronic - complications | Renal Insufficiency, Chronic - drug therapy | Proteinuria - drug therapy | Parathyroid Hormone - metabolism | Ergocalciferols - administration & dosage | Female | Aged | Hyperparathyroidism, Secondary - etiology | Proteinuria - complications | Index Medicus
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 05/2018, Volume 154, Issue 6, pp. S-719 - S-719
Journal Article
American journal of nephrology, ISSN 0250-8095, 02/2015, Volume 40, Issue 6, pp. 535 - 545
Original Report: Patient-Oriented, Translational Research | Parathyroid hormone (PTH) | Vitamin D | Calcifediol (25-hydroxyvitamin D | ) | Secondary hyperparathyroidism (SHPT) | Vitamin D insufficiency | Calcitriol (1,25-dihydroxyvitamin D | Chronic kidney disease (CKD) | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Calcifediol - administration & dosage | Calcifediol - blood | Double-Blind Method | Hyperparathyroidism, Secondary - drug therapy | Humans | Middle Aged | Vitamin D Deficiency - drug therapy | Male | Parathyroid Hormone - blood | Renal Insufficiency, Chronic - complications | Vitamin D - blood | Renal Insufficiency, Chronic - blood | Hyperparathyroidism, Secondary - blood | Vitamin D Deficiency - blood | Adult | Female | Vitamin D - analogs & derivatives | Aged | Vitamins - blood | Hyperparathyroidism, Secondary - etiology | Vitamin D Deficiency - etiology | Delayed-Action Preparations | Vitamins - administration & dosage | Chronic kidney failure | Parathyroid hormone | Mortality | Cytochrome P-450 | Calcifediol | Alfacalcidol | Health aspects | Hyperparathyroidism | Index Medicus
Journal Article
American journal of nephrology, ISSN 0250-8095, 10/2016, Volume 44, Issue 4, pp. 316 - 325
Original Report: Patient-Oriented, Translational Research | Chronic kidney disease | Calcifediol (25-hydroxyvitamin D3) | Vitamin D | Vitamin D insufficiency | Parathyroid hormone | Secondary hyperparathyroidism | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Humans | Middle Aged | Vitamin D Deficiency - drug therapy | Male | Parathyroid Hormone - blood | Renal Insufficiency, Chronic - complications | Calcium - blood | Calcifediol - adverse effects | Vitamin D Deficiency - blood | Hyperparathyroidism - blood | Hyperparathyroidism - drug therapy | Female | Vitamin D Deficiency - etiology | Hyperparathyroidism - etiology | Glomerular Filtration Rate | Double-Blind Method | Calcifediol - therapeutic use | Calcium - urine | Vitamins - therapeutic use | Creatinine - urine | Renal Insufficiency, Chronic - physiopathology | Vitamin D - blood | Vitamins - adverse effects | Fibroblast Growth Factors - blood | Phosphorus - blood | Delayed-Action Preparations - therapeutic use | Vitamin D - analogs & derivatives | Aged | 24,25-Dihydroxyvitamin D 3 - blood | Drugs | Chronic kidney failure | Controlled release preparations | Calcifediol | Dosage and administration | Alfacalcidol | Drug therapy | Hyperparathyroidism | Controlled release | Index Medicus
Journal Article
American journal of nephrology, ISSN 0250-8095, 11/2007, Volume 28, Issue 1, pp. 97 - 106
Original Report: Patient-Oriented, Translational Research | Chronic renal failure | Chronic renal insufficiency | Secondary hyperparathyroidism | Paricalcitol | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Hyperparathyroidism, Secondary - drug therapy | Administration, Oral | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Treatment Outcome | Parathyroid Hormone - blood | Receptors, Calcitriol - metabolism | Kidney Failure, Chronic - therapy | Calcium - blood | Hyperparathyroidism, Secondary - blood | Ergocalciferols - adverse effects | Peritoneal Dialysis | Phosphorus - blood | Kidney Failure, Chronic - complications | Aged, 80 and over | Placebos | Adult | Ergocalciferols - administration & dosage | Female | Aged | Hyperparathyroidism, Secondary - etiology | Renal Dialysis | Index Medicus
Journal Article
BMC medicine, ISSN 1741-7015, 10/2017, Volume 15, Issue 1, pp. 181 - 181
Single dose combination treatment | Artefenomel | Piperaquine | Uncomplicated Plasmodium falciparum malaria | Modelling and simulation | Dose-response | Phase II B | Children | Pharmacokinetics | OZ439 | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Malaria, Falciparum - drug therapy | Double-Blind Method | Humans | Middle Aged | Africa | Artemisinins - administration & dosage | Child, Preschool | Infant | Male | Treatment Outcome | Antimalarials - therapeutic use | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Asian Continental Ancestry Group | Antimalarials - administration & dosage | Plasmodium falciparum - genetics | Adolescent | Adult | Female | Quinolines - therapeutic use | Drug Therapy, Combination | Child | Plasmodium falciparum | Complications and side effects | Usage | Care and treatment | Malaria | Antimalarials | Dosage and administration | Research | Simulation methods | Vector-borne diseases | Mortality | Erythrocytes | Clinical trials | Objectives | Infections | Pharmacology | Parasites | Patients | Evidence-based medicine | Genotype & phenotype | Adults | Drug dosages | Index Medicus | Malà ria | Dose–response
Journal Article
Nephrology, dialysis, transplantation, ISSN 0931-0509, 05/2004, Volume 19, Issue 5, pp. 1174 - 1181
Costs | Vitamin D | Hospitalizations | Haemodialysis | Multivariate | Hyperparathyroidism | Outcomes | Transplantation | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Glomerulonephritis | Emergency and intensive care: renal failure. Dialysis management | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Nephropathies. Renovascular diseases. Renal failure | Transfusions. Complications. Transfusion reactions. Cell and gene therapy | Nephrology. Urinary tract diseases | Biological and medical sciences | Intensive care medicine | Medical sciences | Blood. Blood and plasma substitutes. Blood products. Blood cells. Blood typing. Plasmapheresis. Apheresis | Hyperparathyroidism, Secondary - drug therapy | Risk Assessment | Humans | Kidney Failure, Chronic - complications | Medical Records | Hospitalization - statistics & numerical data | Ergocalciferols - therapeutic use | Treatment Outcome | Retrospective Studies | Calcitriol - therapeutic use | Hyperparathyroidism, Secondary - etiology | Renal Dialysis | Index Medicus
Journal Article
American journal of kidney diseases, ISSN 0272-6386, 2007, Volume 49, Issue 6, pp. 814 - 823
Nephrology | hemodialysis | secondary hyperparathyroidism | end-stage renal disease | children | Paricalcitol | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Non tumoral diseases. Target tissue resistance. Benign neoplasms | Nephropathies. Renovascular diseases. Renal failure | Renal failure | Nephrology. Urinary tract diseases | Biological and medical sciences | Endocrinopathies | Medical sciences | Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases) | Hyperparathyroidism - etiology | Double-Blind Method | Humans | Bone Density Conservation Agents - therapeutic use | Child, Preschool | Ergocalciferols - therapeutic use | Male | Bone Density Conservation Agents - administration & dosage | Parathyroid Hormone - blood | Kidney Failure, Chronic - therapy | Calcium - blood | Kidney Failure, Chronic - blood | Phosphorus - blood | Adolescent | Kidney Failure, Chronic - complications | Hyperparathyroidism - blood | Hyperparathyroidism - drug therapy | Adult | Ergocalciferols - administration & dosage | Female | Infusions, Intravenous | Child | Renal Dialysis | Index Medicus
Journal Article
American journal of kidney diseases, ISSN 0272-6386, 2008, Volume 51, Issue 4, pp. B57 - B57
Journal Article
10.
Full Text
Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis
Pediatric nephrology (Berlin, West), ISSN 0931-041X, 5/2005, Volume 20, Issue 5, pp. 622 - 630
Phosphorus | Renal osteodystrophy | Calcium | End stage renal disease | Secondary hyperparathyroidism | Pediatrics | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Injections, Intravenous | Hyperparathyroidism, Secondary - drug therapy | Calcium Compounds | Humans | Calcitriol - adverse effects | Child, Preschool | Male | Parathyroid Hormone - blood | Chronic Kidney Disease-Mineral and Bone Disorder - drug therapy | Kidney Failure, Chronic - therapy | Calcitriol - administration & dosage | Calcium - blood | Calcium Channel Agonists - administration & dosage | Acetates - administration & dosage | Adolescent | Kidney Failure, Chronic - complications | Phosphates - blood | Female | Calcium Carbonate - administration & dosage | Calcium Channel Agonists - adverse effects | Chronic Kidney Disease-Mineral and Bone Disorder - etiology | Hyperparathyroidism, Secondary - etiology | Child | Renal Dialysis | Index Medicus
Journal Article
American journal of nephrology, ISSN 0250-8095, 04/2006, Volume 26, Issue 1, pp. 105 - 114
Original Report: Laboratory Investigation | Hypercalcemia | Once-daily dosing, paricalcitol | Vitamin D | Intermittent dosing, paricalcitol | Hyperphosphatemia | Pulse dosing, paricalcitol | Vitamin D receptor activator | Nephrology. Urinary tract diseases | Biological and medical sciences | Endocrinopathies | Non tumoral diseases. Target tissue resistance. Benign neoplasms | Medical sciences | Parathyroids. Parafollicular cells. Cholecalciferol. Phosphocalcic homeostasis (diseases) | Prospective Studies | Double-Blind Method | Drug Administration Schedule | Hyperparathyroidism, Secondary - drug therapy | Humans | Middle Aged | Male | Parathyroid Hormone - blood | Vitamins - pharmacokinetics | Calcium - blood | Capsules | Phosphorus - blood | Ergocalciferols - pharmacokinetics | Aged, 80 and over | Adult | Ergocalciferols - administration & dosage | Female | Aged | Kidney Diseases - complications | Chronic Disease | Vitamins - administration & dosage | Index Medicus
Journal Article
American journal of nephrology, ISSN 0250-8095, 02/2015, Volume 40, Issue 6, pp. I - VI
Journal Article
Critical care medicine, ISSN 0090-3493, 12/2006, Volume 34, p. A78
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 11/1996, Volume 98, Issue 10, pp. 2381 - 2387
urolithiasis | hydroxycitrate | hypokalemia | citrate | acidosis | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | ATP Citrate (pro-S)-Lyase - antagonists & inhibitors | Kidney Cortex - metabolism | ATP Citrate (pro-S)-Lyase - immunology | ATP Citrate (pro-S)-Lyase - physiology | ATP Citrate (pro-S)-Lyase - genetics | Rats | Immunoblotting | Male | Food, Formulated | Rats, Sprague-Dawley | Acidosis, Renal Tubular - metabolism | RNA, Messenger - biosynthesis | Blotting, Northern | Citrates - pharmacology | Kidney - metabolism | Animals | Citrates - metabolism | Hypokalemia - metabolism | Urinary Calculi - metabolism | Index Medicus | Abridged Index Medicus
Journal Article